2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - La Nouvelle A-B
Technology and Procedures, Omics Technologies, Bioinformatics, Profiling, Treatment Considerations, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Biological Processes, Genomics, Immune Mechanism, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Translational Research, Study Population, Human, Adult
PAPER

694 Proteogenomic profiling resolves proliferation risk to the MCM protein complex and defines genomic alteration-specific protein states in newly diagnosed multiple myeloma

Yizhe Song, Mark Fiala, MSW, PhD2, Michael J. Slade, MD, MSCI3, Julie Fortier, PhD4, Anand Kadakia, MD5, Rushin Patel, MD6, Kazuhito Sato, MD, PhD7, Reyka G. Jayasinghe, PhD8, Julia Tianjiao Wang, PhD9, Kiran Vij10, Chaitanya Acharya, PhD11, Tao Liu12, George Mulligan, PhD13, Ravi Vij, MD, MBA14, Li Ding, PhD15
1 Washington University School of Medicine,, SAINT LOUIS, Missouri, United States
2 Washington University School of Medicine,, SAINT LOUIS, Missouri, United States
3 Washington University School of Medicine,, SAINT LOUIS, Missouri, United States
4 Washington University School of Medicine,, SAINT LOUIS, Missouri, United States
5 Washington University School of Medicine,, SAINT LOUIS, Missouri, United States
6 Washington University School of Medicine,, SAINT LOUIS, Missouri, United States
7 Washington University School of Medicine,, SAINT LOUIS, Missouri, United States
8 Washington University School of Medicine,, SAINT LOUIS, Missouri, United States
9 Washington University School of Medicine,, SAINT LOUIS, Missouri, United States
10 Washington University School of Medicine, SAINT LOUIS, Missouri, United States
11 Multiple Myeloma Research Foundation (MMRF), Norwalk, Connecticut, United States
12 Pacific Northwest National Laboratory, Richland, Washington, United States
13 Multiple Myeloma Research Foundation (MMRF), Norwalk, Connecticut, United States
14 Washington University School of Medicine,, SAINT LOUIS, Missouri, United States
15 Washington University School of Medicine,, SAINT LOUIS, Missouri, United States

Background: Cell proliferation is one of the strongest continuous predictors of outcome in newly diagnosed multiple myeloma (NDMM) and has traditionally been measured using gene expression signatures such as GEP70 and SKY92. However, it remains unclear whether this prognostic signal can be identified directly at the protein level and which protein complexes are responsible for it.

Methods: We performed integrated proteomic, phosphoproteomic, transcriptomic, and genomic analyses in baseline samples from 114 patients with NDMM, including measurements of 6,610 proteins and 5,152 phosphorylation sites. A treatment-homogeneous cohort of 64 patients was analyzed using covariate-adjusted Cox models and nested cross-validation. Findings were evaluated in four independent cohorts: the DSMM proteomic cohort (n=100), UAMS transcriptomic cohort (n = 559), HOVON-65 trial (n = 328), and the randomized APEX relapsed-myeloma trial (n=156). Relationships between protein expression and recurrent genomic abnormalities, including RAS, TP53, DIS3 mutations, chromosome 1q gain and chromosome 1p deletion were also examined.

Results: Global proteomic analysis showed that the proliferation-related risk signal converged on the minichromosome maintenance 2–7 (MCM2–7) DNA replication-licensing complex. Higher MCM protein abundance was associated with significantly worse overall survival (OS; hazard ratio [HR] 3.12, P < 0.0001) and progression-free survival (PFS; HR 2.01, P < 0.0001). This association remained significant after adjusting for plasma-cell fraction, confirming a tumor-cell-intrinsic signal. MCM proteins ranked highest in nested cross-validation, with OS risk independently validated in the DSMM and UAMS cohorts. Increased MCM abundance also characterized the proliferation subgroup in HOVON-65. MCM expression was not prognostic in the relapsed APEX trial, suggesting that its prognostic value may be specific to newly diagnosed disease. Phosphoproteomic analysis reinforced the MCM-dependent activation: MCM2 phosphosites were among the strongest adverse phosphoproteomic signals, while the association of CDC7 kinase activity with poor prognosis attenuated after adjustment for total MCM abundance, indicating that the adverse effect of CDC7 is mediated through activation of the MCM complex rather than through an independent pathway.

After controlling for co-occurring genomic abnormalities, chromosome 1q gain defined a distinct 130-protein program. All 52 measured proteins encoded on chromosome 1q were increased and showed complete agreement with corresponding transcript levels, whereas all 56 decreased proteins were encoded outside chromosome 1q. CACYBP, located at 1q25.1, emerged as a candidate adverse driver (HR 1.85, P = 0.005), with its association with poor PFS remaining after adjustment for 1q gain (HR 2.09, P = 0.006). Proteins suppressed outside chromosome 1q were enriched for regulators of plasma-cell immunoreceptor signaling, including PLCG2, DOCK2, INPP5D, DOK3, and STAP1. Direct protein measurements also demonstrated a 2.55-fold increase in the BCL2-to-MCL1 ratio in patients with t(11;14), supporting increased relative BCL2 dependence in this subgroup. Integrated genetic and phosphoproteomic analysis also identified distinct downstream effects of genomic abnormalities. RAS mutations were linked to marked loss of cortactin and increased RB1 pT12 phosphorylation; TP53 mutations to elevated Cyclin Y and DDX24 pS82; and DIS3 to increased EXOSC9 and reduced IFNGR1. Chromosome 1p loss was characterized by depletion of F-actin capping proteins (PACSIN2, CAPZA1, CAPZB) and increased LARP1 pS517 phosphorylation.

Conclusions:  Proteomic profiling identifies the MCM2–7 DNA replication-licensing complex as the central protein-level mediator of the proliferation-related prognostic signal in newly diagnosed multiple myeloma. The study also defines the protein architecture associated with chromosome 1q gain, identifies CACYBP as a candidate adverse driver, and reveals suppression of immunoreceptor-signaling proteins outside chromosome 1q. These findings provide a protein-level map connecting recurrent genomic abnormalities with cellular pathways in primary multiple myeloma. Integration with MMRF CyTOF data may further validate these programs at cellular resolution and define their clinical relevance.

Mark Fiala, MSW, PhD: No relevant conflicts of interest to declare.